This year, organizers are holding the conference from July 20 to 25 in Melbourne, Australia. It has already been the site of some encouraging research announcements. We've highlighted one in this week's FierceDiagnostics, about a biomarker that might help spot patients who would respond best to a promising new HIV vaccine.
We all know the life sciences industry produces plenty of hype about new diagnostic advances, cutting-edge treatments and lifesaving surgeries. Many are profoundly amazing and life-changing inventions that have saved countless lives. But the truth is that much of patient diagnosis and care remains guesswork, trial, error and hope. Read more >>
POPULAR COMMENT THREADS
Revenue isn't yet growing fast enough for cancer diagnostics darling Foundation Medicine, making the recent New York State Department of Health approval of the Massachusetts company's two initial cancer tests all the more significant.
Quest Diagnostics saw its net income drop and earnings per share decline during the 2014 second quarter, as the company absorbed costs stemming from restructuring and M&A integration expenses. The New Jersey diagnostics giant has also adjusted full-year revenue projections for 2014.
Unfortunately, the biggest news coming out of the 20th International AIDS Conference involves the researchers who were killed on their way there.
Startup GeneCentric Diagnostics pulled in $5 million in new Series A financing, according to reports from The Herald-Sun and Dow Jones VentureWire, among other media organizations. The money will help the North Carolina startup advance further development of gene-based diagnostic products designed to enable personalized treatments.
A three-year-old Pennsylvania startup pulled in the first tranche of a $11.6 million financing designed to help bring its first needle-based, minimally invasive diagnostic tool through regulatory clearance and commercial launch.
From Our Sister Sites
Bristol-Myers Squibb's melanoma drug Yervoy and clot-fighter Eliquis helped boost its earnings past analyst forecasts, with $333 million in profits on $3.9 billion in revenue.
Blame a strong Swiss franc on any falling sales and profits Roche put up in the first half of 2014, the company said Thursday. The Swiss pharma's cancer drugs certainly didn't cause the decline, with newcomers Perjeta and Kadcyla helping power the group with especially noteworthy revenue gains.